Back to School: How biopharma can reboot drug development. Access exclusive analysis here

IFN-alpha XL: Preliminary Phase I/II data

In an open-label Phase I/II trial in up to 42

Read the full 109 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE